Blinded Sample Size Reestimation with Negative Binomial Counts in Superiority and Non-inferiority Trials

Summary

Background: In the planning of clinical trials with count outcomes such as the number of exacerbations in chronic obstructive pulmonary disease (COPD) often considerable uncertainty exists with regard to the overall event rate and the level of overdispersion which are both crucial for sample size calculations.

Objectives: To develop a sample size reestimation strategy that maintains the blinding of the trial, controls the type I error rate and is robust against misspecification of the nuisance parameters in the planning phase in that the actual power is close to the target.

Methods: The operation characteristics of the developed sample size reestimation procedure are investigated in a Monte Carlo simulation study.

Results: Estimators of the overall event rate and the overdispersion parameter that do not require unblinding can be used to effectively adjust the sample size without inflating the type I error rate while providing power values close to the target.

Conclusions: If only little information is available regarding the size of the overall event rate and the overdispersion parameter in the design phase of a trial, we recommend the use of a design with sample size reestimation as the one suggested here. Trials in COPD are expected to benefit from the proposed sample size reestimation strategy.

Keywords

Internal pilot study - sample size - clinical trial - chronic obstructive pulmonary disease - COPD

• References

• 1 Wittes J, Brittain E. The role of internal pilot studies in increasing efficiency of clinical trials. Statistics in Medicine 1990; 9: 65-72.
• 2 Friede T, Kieser M. Sample size recalculation in internal pilot study designs: A review. Biometrical Journal 2006; 48: 537-555.
• 3 Proschan MA. Sample size re-estimation in clinical trials. Biometrical Journal 2009; 51: 348-357.
• 4 Cook RJ, Bergeron PJ, Boher JM, Lie Y. Two-stage design of clinical trials involving recurrent events. Statistics in Medicine 2009; 28: 2617-2638.
• 5 Friede T, Schmidli H. Blinded sample size reestimation with count data: Methods and applications in multiple sclerosis. Statistics in Medicine 2010; 29: 1145-1156. .
• 6 McCullagh P, Nelder JA. Generalized Linear Models (2nd ed). Chapman & Hall: London; 1989
• 7 World Health Organization (WHO).. Chronic obstructive pulmonary disease (COPD). Fact sheet N°315, May 2008. www.who.int/mediacentre/factsheets/fs315/en/print.html Accessed November 2 2009
• 8 Food and Drug Administration (FDA).. Guidance for industry – Chronic obstructive pulmonary disease: Developing drugs for treatment. Draft guidance 2007
• 9 Suissa S. Statistical treatment of exacerbations in therapeutic trials of chronic obstructive pulmonary disease. American Journal of Respiratory Critical Care Medicine 2006; 173: 842-846.
• 10 Aaron SD, Fergusson D, Marks GB, Suissa S, Vandemheen KL, Doucette S, Maltais F, Bourbeau JF, Goldstein RS, Balter M, O’Donnell D, FitzGerald M. for the Canadian Thoracic Society/Canadian Respiratory Clinical Research Consortium. Counting, analyzing and reporting exacerbations of COPD in randomized controlled trials. Thorax 2008; 63: 122-128.
• 11 Keene ON, Calvery PMA, Jones PW, Vestbo J, Anderson JA. Statistical analysis of exacerbation rates in COPD: TRISTAN and ISOLDE revisited. European Respiratory Journal 2008; 32: 17-24.
• 12 Keene ON, Jones MRK, Lane PW, Anderson J. Analysis of exacerbation rates in asthma and chronic obstructive pulmonary disease: example from the TRISTAN study. Pharmaceutical Statistics 2007; 6: 89-97.
• 13 Ferguson GT, Anzueto A, Fei R, Emmett A, Knobil K, Kalberg C. Effect of fluticasone propionate/salmeterol (250/50 μg) or salmeterol (50 μg) on COPD exacerbations. Respiratory Medicine 2008; 102: 1099-1108.
• 14 Anzueto A, Ferguson GT, Feldman G, Chinsky K, Seibert A, Emmett A, Knobil K, O’Dell D, Kalberg C, Crater G. Effect of flucticasone propionate/ salmetrerol (250/50) on COPD exacerbations and impact on patient outcomes. Journal of Chronic Obstructive Pulmonary Disease 2009; 6: 320-329.
• 15 Hilbe JM. Negative Binomial Regression. Cambridge University Press; Cambridge: 2007
• 16 Friede T, Kieser M. A comparison of methods for adaptive sample size adjustment. Statistics in Medicine 2001; 20: 3861-3873.
• 17 Friede T, Kieser M. Sample size recalculation for binary data for internal pilot study designs. Pharmaceutical Statistics 2004; 3: 269-279.
• 18 Friede T, Kieser M. Blinded sample size reassessment in noninferiority and equivalence trials. Statistics in Medicine 2003; 22: 995-1007.
• 19 Friede T, Mitchell C, Müller-Velten G. Blinded sample size reestimation in non-inferiority trials with binary endpoints. Biometrical Journal 2007; 49: 903-916.
• 20 International Conference on Harmonisation (ICH).. ICH Harmonised Tripartite Guideline E9: Statistical Principles for Clinical Trials. Statistics in Medicine 1999; 18: 1905-1942.
• 21 European Medicines Agency (EMEA).. Reflection paper on methodological issues in confirmatory clinical trials planned with an adaptive design. CHMP/EWP/2459/02 2007
• 22 Food and Drug Administration (FDA).. Guidance for industry – Adaptive design clinical trials for drugs and biologics. Draft guidance 2010
• 23 Friede T, Kieser M. Blinded sample size recalculation for clinical trials with normal data and baseline adjusted analysis. Pharmaceutical Statistics 2010 DOI 10.1002/pst.398.
• 24 Friede T, Kieser M. Reassessment of sample size in internal pilot study designs for non-inferiority trials evaluated with ANCOVA. Methods Inf Med 2010 DOI 10.3414/ME09-01-0063.
• 25 Crofton HD. A quantitative approach to parasitism. Parasitology 1971; 62: 179-193.
• 26 van den Elskamp IJ, Knol DL, Uitdehaag BMJ, Bark-hof F. The distribution of new enhancing lesion counts in multiple sclerosis: further explorations. Multiple Sclerosis 2009; 15: 42-49.